Efficacy and Durability of Exenatide in Combination with Pioglitazone vs. Basal-Bolus Insulin in Poorly Controlled Type 2 Diabetic Patients: The QATAR Study

被引：0
|
作者：
Abdul-Ghani, Muhammad
Mujahed, Osama
Mujahed, Ayman
Hassoun, Shai-Maa
Alkasem, Meis
Abou Samra, Abdel Badi
Zirie, Mahmoud
Defronzo, Ralph A.
Jayyousi, Amin
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
188-OR
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [31] Short-term continuous basal-bolus intravenous insulin infusion does not affect endothelial function in poorly controlled type 2 diabetes mellitus patients
    Czupryniak, Leszek
    Saryusz-Wolska, Malgorzata
    Pawlowski, Maciej
    Borkowska, Anna
    Loba, Jerzy
    DIABETES, 2006, 55 : A108 - A108
  • [32] Substitution of insulin by exenatide in bad controlled type 2 diabetic patients: efficacy and predictive factors
    Barthelemy, M.
    Sanchis, S. Boullu
    Moreau, F.
    Reix, N.
    Pinget, M.
    Sigrist, S.
    Jeandidier, N.
    MINERVA ENDOCRINOLOGICA, 2015, 40 (03) : 155 - 161
  • [33] Efficacy and Safety of a Basal-Bolus Regimen of Basal Insulin Plus Insulin Glulisine in Patients With Type 2 Diabetes: A Pooled Analysis of 5 Clinical Trials
    Dailey, George
    Lin, Jay
    Wang, Edward
    DIABETES, 2012, 61 : A284 - A284
  • [34] Efficacy and Safety of Intensive Versus Nonintensive Supplemental Insulin With a Basal-Bolus Insulin Regimen in Hospitalized Patients With Type 2 Diabetes: A Randomized Clinical Study
    Vellanki, Priyathama
    Cardona, Saumeth
    Galindo, Rodolfo J.
    Urrutia, Maria A.
    Pasquel, Francisco J.
    Davis, Georgia M.
    Fayfman, Maya
    Migdal, Alexandra
    Peng, Limin
    Umpierrez, Guillermo E.
    DIABETES CARE, 2022, 45 (10) : 2217 - 2223
  • [35] Basal-Bolus vs. Premixed Insulin Regimen in Type 2 Diabetes: Comparison of Clinical Outcomes from Randomised Controlled Trials and Real-World Data
    Anyanwagu, Uchenna C.
    Mamza, Jil B.
    Donnelly, Richard
    Idris, Iskandar
    DIABETES, 2017, 66 : A259 - A259
  • [36] iGlarLixi vs. Basal-Bolus (BB) or Premixed Insulin in Older Adult Ethnic Minorities with Type 2 Diabetes (T2D)
    Umpierrez, Guillermo
    Gill, Jasvinder
    Hood, David
    Li, Xuan
    Nunez, Ana
    DIABETES, 2024, 73
  • [37] Proportion and characteristics of patients with type 2 diabetes initiating basal insulin therapy with a basal-bolus regimen in China
    Zhang, Puhong
    Zhang, Heng
    Zhu, Dongshan
    Li, Xian
    Ji, Jiachao
    Zhao, Fang
    Lu, Juming
    Jia, Weiping
    Ji, Linong
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34
  • [38] Comparison of dinner with bedtime administration of insulin glargine in type 1 diabetic patients treated with basal-bolus regimen
    Grimaldi, A.
    Vialettes, B.
    Blayo, A.
    Brun, J. M.
    Halimi, S.
    DIABETES & METABOLISM, 2007, 33 (02) : 121 - 128
  • [39] Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen
    Bergenstal, Richard M.
    Peyrot, Mark
    Dreon, Darlene M.
    Aroda, Vanita R.
    Bailey, Timothy S.
    Brazg, Ronald L.
    Frias, Juan P.
    Johnson, Mary L.
    Klonoff, David C.
    Kruger, Davida F.
    Ramtoola, Shenaz
    Rosenstock, Julio
    Serusclat, Pierre
    Weinstock, Ruth S.
    Naik, Ramachandra G.
    Shearer, David M.
    Zraick, Vivien
    Levy, Brian L.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (05) : 273 - 285
  • [40] Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes
    Bebakar, Wan Mohamaed Wan
    Chaykin, Louis
    Herslov, Malene Lundgren
    Rasmussen, Soren
    DIABETES THERAPY, 2017, 8 (01) : 197 - 205
12345